Back to Search

MICHAEL ALBOM, M.D.

M.D.

MOHS-Micrographic Surgery Physician

NPI: 1336291657IndividualAccepts Medicare

Specialties, Licenses & Credentials

MOHS-Micrographic Surgery PhysicianPrimary

Dermatology — MOHS-Micrographic Surgery

Code: 207ND0101X

120823(NY)

CMS Specialties

PrimaryDERMATOLOGY

Additional

PLASTIC AND RECONSTRUCTIVE SURGERY

Education

BOSTON UNIVERSITY SCHOOL OF MEDICINE

Class of 1970

Research & Publications (10)

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
PMID 19249873·Biochemistry·2009
7-preclinical
TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
PMID 18343109·Bioorg Med Chem Lett·2008
7-preclinical
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
PMID 18308565·Bioorg Med Chem Lett·2008
7-preclinical
1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
PMID 17239587·Bioorg Med Chem Lett·2007
7-preclinical
Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
PMID 16890434·Bioorg Med Chem Lett·2006
7-preclinical
Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
PMID 16460933·Bioorg Med Chem Lett·2006
7-preclinical
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
PMID 16254137·Blood·2006
8-other
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
PMID 14640546·J Med Chem·2003
7-preclinical
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
PMID 14522925·Cancer Res·2003
7-preclinical
Tuesdays with Morrie.
PMID 11907999·Manag Care·2002
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
33 E 70TH ST, 1F
NEW YORK, NY 10021

Location

Practice Location

33 E 70TH ST, NEW YORK, NY
(212) 517-2121

Quick Facts

NPI
1336291657
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
56
Publications
10

Are you this provider?

Claim Your Profile